Bazedoxifene
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
| |
| Bazedoxifene
| |
| Systematic (IUPAC) name | |
| 1-[4-(2-azepan-1-ylethoxy)benzyl]-2-
(4-hydroxyphenyl)-3-methyl-1H-indol-5-ol | |
| Identifiers | |
| CAS number | |
| ATC code | ? |
| PubChem | |
| Chemical data | |
| Formula | C30H34N2O3 |
| Mol. mass | 470.603 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
|
WikiDoc Resources for Bazedoxifene | |
|
Articles | |
|---|---|
|
Most recent articles on Bazedoxifene Most cited articles on Bazedoxifene | |
|
Media | |
|
Powerpoint slides on Bazedoxifene | |
|
Evidence Based Medicine | |
|
Clinical Trials | |
|
Ongoing Trials on Bazedoxifene at Clinical Trials.gov Clinical Trials on Bazedoxifene at Google
| |
|
Guidelines / Policies / Govt | |
|
US National Guidelines Clearinghouse on Bazedoxifene
| |
|
Books | |
|
News | |
|
Commentary | |
|
Definitions | |
|
Patient Resources / Community | |
|
Patient resources on Bazedoxifene Discussion groups on Bazedoxifene Patient Handouts on Bazedoxifene Directions to Hospitals Treating Bazedoxifene Risk calculators and risk factors for Bazedoxifene
| |
|
Healthcare Provider Resources | |
|
Causes & Risk Factors for Bazedoxifene | |
|
Continuing Medical Education (CME) | |
|
International | |
|
| |
|
Businness | |
|
Experimental / Informatics | |
Bazedoxifene is a selective estrogen receptor modulator (SERM), developed by Wyeth Pharmaceuticals, undergoing clinical evaluation for the prevention and treatment of postmenopausal osteoporosis. It is currently in the early phases of review by the United States' Food and Drug Administration. When approved, bazedoxifene is to be sold by Wyeth under the tradename Viviant™. Bazedoxifene's combination with conjugated estrogens, Aprela™, is currently undergoing Phase III studies.
Wyeth received an approvable letter for Bazedoxifene in late April 2007. The FDA called for final safety and efficacy data from Phase III studies, and acceptable valuation of manufacturing and testing facilities where problems were found earlier in the year. Wyeth is working with the FDA to resolve these issues, and expects an FDA action date at year end.
CITATIONS
BROWN, EMILY. Wyeth's osteoporosis drug cut risk of new fractures. Retrieved on 2007-09-28. Wyeth Receives Approvable Letter from FDA for Bazedoxifene for the Prevention of Postmenopausal Osteoporosis. Retrieved on 2007-09-28.
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .
